These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 31912450)

  • 1. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
    Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
    J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing.
    Gu X; Wang D; Xu Z; Wang J; Guo L; Chai R; Li G; Shu Y; Li H
    Genome Biol; 2021 Mar; 22(1):86. PubMed ID: 33752742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
    Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
    Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene editing based hearing impairment research and therapeutics.
    Kang W; Sun Z; Zhao X; Wang X; Tao Y; Wu H
    Neurosci Lett; 2019 Sep; 709():134326. PubMed ID: 31195050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.
    Gao X; Tao Y; Lamas V; Huang M; Yeh WH; Pan B; Hu YJ; Hu JH; Thompson DB; Shu Y; Li Y; Wang H; Yang S; Xu Q; Polley DB; Liberman MC; Kong WJ; Holt JR; Chen ZY; Liu DR
    Nature; 2018 Jan; 553(7687):217-221. PubMed ID: 29258297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9; A robust technology for producing genetically engineered plants.
    Farooq R; Hussain K; Nazir S; Javed MR; Masood N
    Cell Mol Biol (Noisy-le-grand); 2018 Nov; 64(14):31-38. PubMed ID: 30511631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9-mediated correction of human genetic disease.
    Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
    Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    Zhu W; Du W; Rameshbabu AP; Armstrong AM; Silver S; Kim Y; Wei W; Shu Y; Liu X; Lewis MA; Steel KP; Chen ZY
    Sci Transl Med; 2024 Jul; 16(755):eadn0689. PubMed ID: 38985856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo.
    Tao Y; Lamas V; Du W; Zhu W; Li Y; Whittaker MN; Zuris JA; Thompson DB; Rameshbabu AP; Shu Y; Gao X; Hu JH; Pei C; Kong WJ; Liu X; Wu H; Kleinstiver BP; Liu DR; Chen ZY
    Nat Commun; 2023 Aug; 14(1):4928. PubMed ID: 37582836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in genome editing for genetic hearing loss.
    Ding N; Lee S; Lieber-Kotz M; Yang J; Gao X
    Adv Drug Deliv Rev; 2021 Jan; 168():118-133. PubMed ID: 32387678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy.
    de Morais CCPL; Correia EM; Bonamino MH; Vasconcelos ZFM
    Hum Gene Ther; 2024 Oct; 35(19-20):781-797. PubMed ID: 39276086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
    Liu C; Zhang L; Liu H; Cheng K
    J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas gene therapy.
    Zhang B
    J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the potential of genome editing CRISPR-Cas9 technology.
    Singh V; Braddick D; Dhar PK
    Gene; 2017 Jan; 599():1-18. PubMed ID: 27836667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
    Zhang X; Wang L; Liu M; Li D
    Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CRISPR/Cas9 system and its applications in crop genome editing.
    Bao A; Burritt DJ; Chen H; Zhou X; Cao D; Tran LP
    Crit Rev Biotechnol; 2019 May; 39(3):321-336. PubMed ID: 30646772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in gene therapy hold promise for treating hereditary hearing loss.
    Jiang L; Wang D; He Y; Shu Y
    Mol Ther; 2023 Apr; 31(4):934-950. PubMed ID: 36755494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome Engineering for Stem Cell Transplantation.
    Argani H
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.